199 related articles for article (PubMed ID: 12403977)
21. Benefit and risk assessment in drug development and utilization: a role for clinical pharmacology.
Honig P
Clin Pharmacol Ther; 2007 Aug; 82(2):109-12. PubMed ID: 17632530
[No Abstract] [Full Text] [Related]
22. Chronicles in drug discovery.
Cole P; Vasiliou S
Drug News Perspect; 2009 Oct; 22(8):500-3. PubMed ID: 20016859
[No Abstract] [Full Text] [Related]
23. List of drugs in development for neurodegenerative diseases. Update June 2007.
Pogacić V; Herrling P
Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
[No Abstract] [Full Text] [Related]
24. Brief review of current research in FXS: implications for treatment with psychotropic medication.
Valdovinos MG
Res Dev Disabil; 2007; 28(6):539-45. PubMed ID: 17034990
[TBL] [Abstract][Full Text] [Related]
25. 'Emancipated' biotechs offer new drugs for neurodegeneration.
Basu P
Nat Med; 2003 Aug; 9(8):981. PubMed ID: 12894143
[No Abstract] [Full Text] [Related]
26. List of drugs in development for neurodegenerative diseases. Update March 2005.
Valentine L; Kwon MO; Herrling P
Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
[No Abstract] [Full Text] [Related]
27. Remarks concerning new tools and methodologies for research and clinical practice.
Kingston R
Thromb Res; 2005; 117(1-2):119-21; discussion 145-51. PubMed ID: 16139871
[No Abstract] [Full Text] [Related]
28. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
Petersen TK
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
[TBL] [Abstract][Full Text] [Related]
29. What is next in ALS clinical trials?
Sorenson EJ
Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
[No Abstract] [Full Text] [Related]
30. Experimental medicine in psychiatry.
Dawson GR; Goodwin G
J Psychopharmacol; 2005 Nov; 19(6):565-6. PubMed ID: 16272178
[No Abstract] [Full Text] [Related]
31. Science, medicine and... the markets.
Pawlotsky JM
J Hepatol; 2006 Sep; 45(3):341-2. PubMed ID: 16854496
[No Abstract] [Full Text] [Related]
32. List of drugs in development for neurodegenerative diseases.
Fischer F; Matthisson M; Herrling P
Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
[No Abstract] [Full Text] [Related]
33. Drugs and clinical trials in neurodegenerative diseases.
Stanzione P; Tropepi D
Ann Ist Super Sanita; 2011; 47(1):49-54. PubMed ID: 21430339
[TBL] [Abstract][Full Text] [Related]
34. A unique biomedical resource at risk.
VandeBerg JL; Zola SM
Nature; 2005 Sep; 437(7055):30-2. PubMed ID: 16136112
[No Abstract] [Full Text] [Related]
35. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
Dambach DM; Andrews BA; Moulin F
Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
[TBL] [Abstract][Full Text] [Related]
36. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
Singh M; Johnson L
Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
[TBL] [Abstract][Full Text] [Related]
37. Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases.
Boldron C; Van der Auwera I; Deraeve C; Gornitzka H; Wera S; Pitié M; Van Leuven F; Meunier B
Chembiochem; 2005 Nov; 6(11):1976-80. PubMed ID: 16208731
[No Abstract] [Full Text] [Related]
38. Human embryonic stem cells: a resource for in vitro neuroscience research?
Norman TR
Neuropsychopharmacology; 2006 Dec; 31(12):2571-2. PubMed ID: 17109013
[No Abstract] [Full Text] [Related]
39. [Theoretic prediction of drug safety and efficacy--drug efficacy].
Ito T; Nakajima M
Nihon Yakurigaku Zasshi; 1996 Sep; 108(3):175-7. PubMed ID: 9091455
[No Abstract] [Full Text] [Related]
40. Targeting disease, not disease targets: Innovative approaches in tackling neurodegenerative disorders.
Griffioen G
IDrugs; 2007 Apr; 10(4):259-63. PubMed ID: 17390249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
